Search results
Showing 841 to 855 of 1835 results for carers
People can comment on our guidance at specific stages in its development.
LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)
NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home
Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency.
In development Reference number: GID-TA11544 Expected publication date: 14 May 2026
In development Reference number: GID-HTE10080 Expected publication date: TBC
Ex-situ machine perfusion devices for extracorporeal preservation of lungs for transplant
In development Reference number: GID-HTE10084 Expected publication date: TBC
In development Reference number: GID-IPG10405 Expected publication date: 19 November 2026
Technology appraisal submission templates and supporting documents
All the templates and supporting documents you need to make a technology appraisals submission with NICE.
We're working with colleagues to ensure that virtual wards are used in a way that maximises the value for patients and the NHS.
In development Reference number: GID-TA11402 Expected publication date: TBC
Awaiting development Reference number: GID-TA11222 Expected publication date: TBC
This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual
Vagus nerve stimulation for refractory epilepsy in children (HTG25)
Evidence-based recommendations on vagus nerve stimulation for refractory epilepsy in children. This involves placing a device under the skin to send a burst of nerve messages through the nerve.
View recommendations for HTG25Show all sections
Sections for HTG25
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Awaiting development Reference number: GID-TA11018 Expected publication date: TBC